Back to today’s briefing

Story perspectives

Hims & Hers Resumes Pill Sales Amid Regulatory Battles

3/3/2026

31 6 Full Breakdown

Summary

Story summary

Hims & Hers Health plans to resume sales of its compounded pill through Strive Pharmacy after halting distribution due to regulatory scrutiny.
The FDA has referred Hims to the Department of Justice over its $49 version of Novo Nordisk's Wegovy.
Hims expands by acquiring Zava in United Kingdom and Eucalyptus in Australia, with a target of $6.5 billion in revenue by 2030, amid litigation with Novo Nordisk and regulatory changes.

1 of 1

Story summary

Hims & Hers Health plans to resume sales of its compounded pill through Strive Pharmacy after halting distribution due to regulatory scrutiny.
The FDA has referred Hims to the Department of Justice over its $49 version of Novo Nordisk's Wegovy.
Hims expands by acquiring Zava in United Kingdom and Eucalyptus in Australia, with a target of $6.5 billion in revenue by 2030, amid litigation with Novo Nordisk and regulatory changes.